On Friday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $49.58 which represents a decrease of $-3.99 or -7.45% from the prior close of $53.57. The stock opened at $53.18 and ...

There aren't many biotechs that are more exciting than Viking Therapeutics (NASDAQ: VKTX) right now. Thanks to its ...

Equity markets have performed well in 2024, but their showing pales next to that of Viking Therapeutics (NASDAQ: VKTX), a mid ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors ...

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead obesity candidate, VK2735, has garnered a lot of attention and is widely ...

Viking isn't a biotech that will need to take out a lot of debt or issue a lot of new shares to get its therapies out the door. Therefore, buying its stock won't leave you at as high of a risk of your ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.